Dana-Farber Cancer Institute

Biography

Paul Richardson earned a medical degree at Medical College of St. Bartholomews Hospital in London. His postdoctoral training included internship in the Departments of Medicine & Surgery at St. Bartholomews Hospital; residency in the Department of Medicine at Newcastle University School of Medicine, Newcastle General and Freeman Hospitals in Newcastle-upon-Tyne; appointment as Chief Resident in Medical Oncology at the Royal Marsden Hospital in London and Surrey; and additional residency training at the Beth Israel Hospital in Boston. He completed fellowships in hematology/oncology and medical oncology at Tufts University School of Medicine, Baystate Medical Center, and Harvard Medical School, Dana-Farber Cancer Institute.

Board certified in internal medicine, medical oncology, and hematology, Dr. Richardson holds leadership positions in several professional bodies and serves on the Editorial Board of the Journal of Clinical Oncology, the Journal of Oncology, and Clinical Cancer Research. He is Chairman of the Multiple Myeloma Research Consortium, Clinical Trials Core, and is a member of the American Society of Clinical Oncology ACRA Hematologic Malignancies Subcommittee. His honors include several Massachusetts General Hospital, Brigham and Womens Hospital, and Dana-Farber Partners in Excellence Awards; The Brigham and Womens Hospital Teaching Scholars Award; and the Dana-Farber Cancer Institutes George Canellos Award for Excellence in Clinical Research and Patient Care.

Dr. Richardson has published more than 140 original articles, and more than 100 reviews, chapters, and editorials in top peer-reviewed journals including the New England Journal of Medicine, Blood, Journal of Clinical Oncology, Leukemia, Clinical Cancer Research, and British Journal of Haematology. Dr. Richardson is a highly sought invited lecturer both nationally and internationally. Currently, he is leading multiple efforts studying the use of combination therapies in relapsed and refractory myeloma, an area of primary interest to him. He is also serving as a principal investigator and study chairman for several clinical trials relating to other areas of myeloma treatment, including the use of combination therapies in earlier disease designed to target resistance and reduce toxicity.